<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01611142</url>
  </required_header>
  <id_info>
    <org_study_id>PROTOCOL 0761-007</org_study_id>
    <nct_id>NCT01611142</nct_id>
  </id_info>
  <brief_title>Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)</brief_title>
  <official_title>Open-Label, Multi-Center, Phase 2 Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the overall response rate of KW-0761 for&#xD;
      the treatment of patients with relapsed or refractory PTCL. KW-0761 targets CCR4. CCR4 is the&#xD;
      receptor for macrophage derived chemokines MDC/CCL22 and TARC/CCL17. Chemokines are&#xD;
      considered to play a role both in the recruitment of immune and inflammatory cells for&#xD;
      anti-tumor response and in the selective homing of neoplastic B and T cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PTCL is a rare and heterogeneous disease that remains difficult to diagnose and treat. In the&#xD;
      majority of PTCL subtypes, patients are of older age (&gt;60 years) and present with advanced&#xD;
      stage disease.With the exception of the ALCL-ALK-positive subtype that responds well to CHOP&#xD;
      combined chemotherapy, most PTCL subtypes become refractory even to aggressive chemotherapy&#xD;
      regimens or relapse. Overall survival of PTCL patients is poor compared with that of&#xD;
      aggressive B-cell lymphomas.Thus, novel and effective therapies are&#xD;
      needed.KW-0761(mogamulizumab) is a defucosylated, humanized, IgG1 mAb with enhanced antibody&#xD;
      dependent cellular cytotoxicity (ADCC)that binds to CCR4, a molecule that is suggested to be&#xD;
      significantly involved in patients with PTCL.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>every 8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Peripheral T-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>KW-0761</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>KW-0761 (mogamulizumab)</intervention_name>
    <description>1 mg/kg administered intravenously weekly x 4 then every other week until progression</description>
    <arm_group_label>KW-0761</arm_group_label>
    <other_name>mogamulizumab</other_name>
    <other_name>POTELIGEO®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥18 years of age at the time of enrollment;&#xD;
&#xD;
          2. Histologically confirmed diagnosis of PTCL as specified below:&#xD;
&#xD;
               -  PTCL-NOS&#xD;
&#xD;
               -  Angioimmunoblastic T-cell lymphoma&#xD;
&#xD;
               -  Anaplastic large cell lymphoma, ALK-positive&#xD;
&#xD;
               -  Anaplastic large cell lymphoma, ALK-negative&#xD;
&#xD;
               -  Transformed mycosis fungoides&#xD;
&#xD;
          3. Failed or intolerant of at least one prior systemic anticancer therapy;&#xD;
&#xD;
          4. ECOG performance status score of ≤ 2 at study entry;&#xD;
&#xD;
          5. At least one site of disease measurable in two dimensions by computed tomography (CT);&#xD;
&#xD;
          6. Subjects who are positive for CCR4 by immunohistochemistry;&#xD;
&#xD;
          7. Resolution of all clinically significant toxic effects of prior cancer therapy to&#xD;
             grade ≤1 (NCI-CTCAE, v.4.0);&#xD;
&#xD;
          8. Adequate hematological hepatic and renal function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject with the following PTCL diagnoses are excluded;&#xD;
&#xD;
               -  Precursor T/NK neoplasms&#xD;
&#xD;
               -  Adult T-cell leukemia-lymphoma&#xD;
&#xD;
               -  T-cell prolymphocytic leukemia&#xD;
&#xD;
               -  T-cell large granular lymphocytic leukemia&#xD;
&#xD;
               -  Aggressive NK-cell leukemia&#xD;
&#xD;
               -  Systemic EBV-positive T-cell lymphoproliferative disorder of childhood&#xD;
&#xD;
               -  Hydroa vacciniforme-like lymphoma&#xD;
&#xD;
               -  Mycosis fungoides, other than transformed mycosis fungoides&#xD;
&#xD;
               -  Sezary Syndrome&#xD;
&#xD;
               -  Primary cutaneous CD30+ disorders: Anaplastic large cell lymphoma and lymphatoid&#xD;
                  papulosis&#xD;
&#xD;
               -  Primary cutaneous CD8+ aggressive epidermotropic cytoxic T-cell lymphoma&#xD;
&#xD;
               -  Primary cutaneous CD4+ small/medium T-cell lymphoma&#xD;
&#xD;
               -  Primary cutaneous gamma-delta T-cell lymphoma&#xD;
&#xD;
               -  Extranodal NK/T T-cell lymphoma-nasal type&#xD;
&#xD;
               -  Enteropathy-associated T-cell lymphoma&#xD;
&#xD;
               -  Hepatosplenic T-cell lymphoma&#xD;
&#xD;
               -  Subcutaneous panniculitis -like T-cell lymphoma&#xD;
&#xD;
               -  Chronic lymphoproliferative disorder of NK cells&#xD;
&#xD;
          2. Have had an invasive solid tumor malignancy in the past five years except non-melanoma&#xD;
             skin cancers, melanoma in situ, cervical carcinoma in situ, ductal/lobular carcinoma&#xD;
             in situ of the breast, or localized prostate cancer with a current PSA of ≤ 0.1 ng/ml&#xD;
             who is currently without evidence of disease;&#xD;
&#xD;
          3. Relapsed less than 75 days of autologous stem cell transplant;&#xD;
&#xD;
          4. History of allogeneic stem cell transplant;&#xD;
&#xD;
          5. Evidence of central nervous system (CNS) metastasis;&#xD;
&#xD;
          6. Psychiatric illness, disability or social situation that would compromise the&#xD;
             subject's safety or ability to provide consent, or limit compliance with study&#xD;
             requirements;&#xD;
&#xD;
          7. Subjects with a history of moderate or severe psoriasis or with psoriasis associated&#xD;
             with systemic symptoms e.g. arthropathy), or with a 1st degree relative with history&#xD;
             of psoriasis that required medical intervention;&#xD;
&#xD;
          8. Significant uncontrolled intercurrent illness;&#xD;
&#xD;
          9. Known or tests positive for human immunodeficiency virus (HIV), hepatitis B or&#xD;
             hepatitis C;&#xD;
&#xD;
         10. Active herpes simplex or herpes zoster;&#xD;
&#xD;
         11. Experienced allergic reactions to monoclonal antibodies or other therapeutic proteins;&#xD;
&#xD;
         12. Known active autoimmune disease will be excluded (For example: Grave's disease;&#xD;
             systemic lupus erythematosus; rheumatoid arthritis; Crohn's disease);&#xD;
&#xD;
         13. Is pregnant (confirmed by beta human chorionic gonadotrophin [β-HCG]) or lactating;&#xD;
             Prohibited Therapies and/or Medications&#xD;
&#xD;
         14. Prior treatment with KW-0761;&#xD;
&#xD;
         15. Initiation of treatment with systemic steroids while on study is only permitted for&#xD;
             acute and brief complications of underlying disease (e.g., hypercalcemia) or for&#xD;
             treatment related side effects;&#xD;
&#xD;
         16. Initiation of treatment with topical steroids while on study is not permitted except&#xD;
             to treat an acute rash;&#xD;
&#xD;
         17. Have had anti-neoplastic chemotherapy, radiation, immunotherapy, or investigational&#xD;
             medications within 4 weeks of screening visit;&#xD;
&#xD;
         18. Subjects on any immunomodulatory drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pier Luigi Zinzani, M.D., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universita di Bologna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Créteil Cedex</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitaliser de Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Bologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum (VUMC)</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen (UMCG)</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Catalá D'Oncologia, Hospital Duran y Reynals</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univesitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37191</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research UK Centre/Southhampton General Hospital</name>
      <address>
        <city>SouthHampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>May 30, 2012</study_first_submitted>
  <study_first_submitted_qc>June 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2012</study_first_posted>
  <last_update_submitted>June 13, 2016</last_update_submitted>
  <last_update_submitted_qc>June 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Monoclonal antibody</keyword>
  <keyword>Peripheral T-cell Lymphoma</keyword>
  <keyword>cancer</keyword>
  <keyword>hematologic malignancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mogamulizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

